CompletedNot Applicable

Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)

8,790 participantsStarted 2011-11

Plain-language summary

The purpose of this study is to determine the proportion of participants that initiate allergen immunotherapy (AIT) upon the recommendation of their physician and the proportion of participants that persist with their AIT throughout the recommended course.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of AR with or without allergic conjunctivitis (AC) * Documented provider-to-patient or parent discussion of AIT as a treatment option Exclusion Criteria: * Participants receiving AIT as an AR treatment without documented provider-to-patient or parent discussion of AIT as a treatment option * Participants receiving immunotherapy for insect sensitivities only * AIT started before 2005

What they're measuring

Percentage of Participants Advised to Start AIT Who Elected Subcutaneous Immunotherapy (SCIT) Shots or Sublingual Immunotherapy (SLIT) Drops

Timeframe: Up to 5 years

Percentage of Participants Who Initiated SCIT or SLIT and Completed 5 Years of Treatment

Timeframe: At 5 years

Duration of Treatment With SCIT or SLIT

Timeframe: Up to 5 years

Reason for Discontinuation of SCIT or SLIT More Than 6 Months Before Completion of the Recommended Course

Timeframe: Up to 5 years

Trial details

NCT IDNCT01549340

SponsorALK-Abelló A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2012-05

Results submitted2014-01-23

View on ClinicalTrials.gov More Perennial Allergic Rhinitis trials